Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495986 | 1.00 | HTR3A (0.47) | HTR3AADRB1MCHR1GAAMAP4K4 | |
| SCHEMBL29495731 | 0.91 | GAA (0.52) | HTR3AADRB1MCHR1GAA | |
| SCHEMBL22969615 | 0.91 | GAA (0.52) | HTR3AADRB1MCHR1GAA | |
| SCHEMBL22969511 | 0.90 | GAA (0.49) | HTR3AADRB1MCHR1GAA | |
| SCHEMBL29495910 | 0.90 | GAA (0.49) | HTR3AADRB1MCHR1GAA | |
| SCHEMBL22969399 | 0.89 | HTR3A (0.42) | HTR3AADRB1MCHR1GAAPDE10A | |
| SCHEMBL29495813 | 0.89 | HTR3A (0.42) | HTR3AADRB1MCHR1GAAPDE10A | |
| SCHEMBL22969237 | 0.84 | MCHR1 (0.49) | MCHR1 | |
| SCHEMBL29495695 | 0.84 | MCHR1 (0.49) | MCHR1 | |
| SCHEMBL22969587 | 0.80 | METAP2 (0.44) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269730-A | 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists | 多曼治疗学公司 | 2022-04-01 | — | — | CN | claimed |
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-09-22 | — | — | US | disclosed |
| CN-114269730-A | 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists | 多曼治疗学公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021023813-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | NPFFR2, NPFFR1, OPRL1 | HTR3A 41/4885ADRB1 115/4885MCHR1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.